Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin.
Clicks: 310
ID: 105223
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
310 views
33 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #4 of 7 articles by views in Clinical case reports
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
This is the first case report of alectinib as a bridge to allo-SCT in a patient with ALK-positive ALCL refractory to both conventional chemotherapies and BV. This report offers a ray of hope for a condition with poor prognosis.
| Reference Key |
nakai2019alectinibclinical
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Nakai, Ritsuko;Fukuhara, Suguru;Maeshima, Akiko Miyagi;Kim, Sung-Won;Ito, Yuta;Hatta, Shunsuke;Suzuki, Tomotaka;Yuda, Sayako;Makita, Shinichi;Munakata, Wataru;Suzuki, Tatsuya;Maruyama, Dai;Izutsu, Koji; |
| Journal | Clinical case reports |
| Year | 2019 |
| DOI |
10.1002/ccr3.2543
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.